LRMR

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 18.00 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Larimar Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Larimar Therapeutics Inc. EPS for the last quarter amounts to -0.61 USD, increased 154.17 % YoY.

Larimar Therapeutics Inc (LRMR) has 65 emplpoyees as of January 09 2026.

Today LRMR has the market capitalization of 279.18M USD.